RBR-5y9y7p7招募中4 期
Safety and Immunogenicity of heterologous or homologous booster after complete vaccination against COVID-19.
Secretaria Municipal de Saúde do Rio de Janeiro0 个研究点开始时间: 2021年12月13日最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Intervention
入排标准
- 年龄范围
- 18Y 至 0（—）
入选标准
- •Age 18 years or older;
- •Have completed the primary vaccination course against COVID-19 with the Coronavac/Butantan, AstraZeneca/Fiocruz or Pfizer vaccines for at least three months;
- •Accepting to participate in the study by signing the Informed Consent Form (ICF);
排除标准
- •Uncontrolled chronic illness (defined as illness that required a significant change in therapy or hospitalization for worsening illness during the 3 months prior to inclusion);
- •Individuals with any severe or progressive neurological disorder, difficult to control seizure disorder or a history of Guillian-Barré syndrome or demyelinating diseases of the central nervous system;
- •Individuals with congenital or acquired immunodeficiency*; or individuals who have received treatment with immunosuppressive therapy, including cytotoxic agents or systemic corticosteroids, e.g. eg, for cancer or an autoimmune disease, within the last 12 months or planned receipt during the study period. If a short-term course (< 14 days) of systemic corticosteroids has been for the treatment of an acute illness, participants should not be included in the study until corticosteroid therapy has been discontinued for at least 30 days prior to the study. A single dose of systemic steroids in a single day is allowed, as well as inhaled/nebulized, intra-articular, intrabursal or topical (skin or eyes) corticosteroids are allowed;
- •Participants who report pregnancy in progress or planning to become pregnant within the next 60 days after inclusion in the study; and postpartum women (up to 45 days after delivery). In the case of women of childbearing age, with an active sexual life and without consistent use of contraceptives, at the researcher's discretion, the participant may be excluded or, alternatively, included, if she agrees to use contraceptives for a period of 60 days after inclusion . In these cases, if necessary, the contraceptive will be provided by the responsible researcher free of charge;
- •Blood transfusion or use of blood products in the last 6 months;
- •Having had a heterologous primary vaccination schedule against Covid-19;
- •Have received a higher number of doses than currently recommended for Covid-19;
- •Having had a serious adverse event to any formulation of the Covid-19 vaccine;
- •Hypersensitivity to the active ingredient or to any of the excipients of the Covid-19 vaccines used in the study;
- •Any condition that, in the investigator's opinion, could compromise the follow-up of the study.
- •* Individuals with HIV infection can be included as long as they have been on regular antiretroviral therapy for at least 3 months, with an undetectable viral load in the last 12 months and CD4 > 350 cells/mm3 at the last exam.
- •Criteria for postponing vaccination, with subsequent reassessment, should be considered:
- •Individuals with acute, mild febrile illnesses until they are 72 hours without fever;
- •Individuals diagnosed with COVID-19 within 4 weeks of symptom onset;
研究者
相似试验
已完成
不适用
Immunogenicity and safety of heterologous and homologous prime-boost schedules with an adenoviral vectored and inactivated SARS-CoV-2 (COVID-19) vaccinesCOVID-19Inactivated vaccineViral vectored vaccineTCTR20210913001The Royal College of Physicians of Thailand400
已完成
不适用
Immunogenicity and Safety Outcome of Homologous and Heterologous Prime-boost of Inactivated Vaccine and Replication-defective Viral Vectors Vaccine Against SARS-CoV2 among Hemodialysis Patients: An Observational Prospective Cohort TrialTCTR20220516002Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand130
已完成
不适用
Safety of Malaria vaccines in Gambian infantsPaediatricsMalariaPACTR201401000363170niversity of Oxford36
已完成
不适用
Safety of Malaria vaccines in Gambian childrePaediatricsMalariaPACTR201204000362870niversity of Oxford36
Unknown
不适用
Safety of Malaria vaccines in Gambian adults , children and infantsMalariaPACTR201008000221638Oxford University, Jenner Institute52